During the February webinar (~48m), Jon Pilcher was asked about the possibility of combining the four disorders into one Phase 3 basket trial.
His answer was that it was unlikely – not only do the different disorders have slightly different endpoints, but also the FDA is going to want efficacy shown in each different disorder anyway.
NEU Price at posting:
$18.65 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)